Attached files
| file | filename |
|---|---|
| 8-K - Xtant Medical Holdings, Inc. | v207953_8k.htm |
| EX-3.2 - Xtant Medical Holdings, Inc. | v207953_ex3-2.htm |
Bacterin
International Holdings, Hires Biologics VP of Business
Development
with Strong Orthopedics Background
BELGRADE, MT, – January X, 2011 –
Bacterin International Holdings, Inc. (“Bacterin”) (OTCBB: BIHI),
today announced that it has appointed Anna Kroll as VP Business Development and
Customer Relations, effective January 17, 2011. Ms. Kroll has
fourteen years of marketing management experience with over eight years managing
the biomaterials business for a Fortune 500 orthopedic medical device
company.
Most
recently, Ms. Kroll was responsible for the global bone cement and bone
substitute product lines at Stryker Orthopedics. She was instrumental in the
introduction and launch of Simplex® P with
Tobramycin, the first antibiotic bone cement approved for use in the US. The
last several years she has been focused on developing the Biologics strategy and
fueling the business development pipeline. Prior to this, Ms. Kroll
managed the lower extremity product portfolio at Kinetikos Medical, Inc.
(acquired by Integra Life Sciences Holdings Corp.), a company focused on the
development, manufacture and distribution of orthopedic implants and surgical
devices for small bone and joint procedures of the foot, ankle, hand, wrist and
elbow.
Guy Cook
commented, “We are fortunate to have found a highly knowledgeable executive who
has proven and valuable experience in business development for
biologics. Anna’s ability to effectively coordinate interaction
between surgeons and sales personnel, as well as product planning and promotion
will be key to furthering the continuing success of Bacterin’s marketing
program. Anna will be instrumental in implementing our product
message through the communication channels and managing our business development
activities to further Bacterin’s product penetration within the surgical
community. She will also be a welcomed addition to our strong
marketing team.”
Ms. Kroll
added, “Bacterin International is at the forefront of biologics with innovative,
high quality products, seeing explosive growth in the market. I
believe Bacterin has the opportunity to revolutionize the biologics market and I
look forward to working with Bacterin’s team of professionals to achieve new
heights for the Company.”
About Bacterin International
Holdings, Inc.
Bacterin
International Holdings, Inc. (“Bacterin”) develops, manufactures and
markets biologics products to domestic and international
markets. Bacterin’s proprietary methods optimize the growth factors
in human allografts to create the ideal stem cell scaffold and promote bone and
other tissue growth. These products are used in a variety of
applications including enhancing fusion in spine surgery, relief of back pain by
facet joint stabilization, promotion of bone fusion in foot and ankle surgery,
promotion of cranial healing following neurosurgery and subchondral bone defect
repair in articulating joint surgeries.
Bacterin’s
Medical Device division develops anti-microbial coatings based upon proprietary
coating technologies. Bacterin develops, employs, and licenses bioactive
coatings for various medical device applications. Bacterin’s
strategic coating initiatives include antimicrobial coatings designed to inhibit
biofilm formation and microbial contamination on medical devices drug delivery,
local (as opposed to systemic) pain management, and anti-thrombotic factors for
medical device applications.
Headquartered
in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art,
fully compliant and FDA registered facility, equipped with four "Class 100"
clean rooms. For further information please visit www.bacterin.com.
Contact:
Yvonne L.
Zappulla
Managing
Director
Grannus
Financial Advisors, Inc.
212-681-4108
or
Guy
Cook
Chairman
& CEO
Bacterin
International Holdings, Inc.
406-388-0480
gcook@bacterin.com
Certain statements in this news
release may constitute “forward-looking” statements within the meaning of
section 21E of the Securities and Exchange Act of 1934. Our
forward-looking statements include earnings guidance and other statements
regarding our expectations and beliefs. The Company believes that its
expectations, as expressed in these statements are based on reasonable
assumptions regarding the risks and uncertainties inherent in achieving those
expectations. These statements are not, however, guarantees of future
performance and actual results may differ materially. Risks and uncertainties
which may cause actual results to be different than expressed or implied in our
forward-looking statements include, but are not limited to, the risk factors
described under the heading “Risk Factors” in Amendment No. 1 to our Form S-1
filed December 7, 2010. The Company expressly disclaims any current
intention to update any forward-looking statements as a result of new
information or future events or developments.